ReviewRNA biology2026
Toward precision oncology: deciphering the circRNA-EMT axis in cancer and its therapeutic implications.
Review in RNA biology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The epithelial-mesenchymal transition is a pivotal driver of cancer metastasis, the leading cause of mortality in solid tumours. Circular RNAs, a unique class of endogenous RNAs characterized by covalently closed loop structures and high stability, have emerged as key regulators in this process. Accumulating evidence reveals widespread dysregulation of circRNAs during EMT, where they function as critical modulators - either promoting or inhibiting the metastatic cascade. This review systematically elucidates the mechanisms by which circRNAs govern EMT, focusing on their interactions with classical signalling pathways (TGF-β, Wnt/β-catenin, and PI3K/AKT) and core EMT-transcription factors. Furthermore, we evaluate the dual promise of circRNAs as stable, disease-specific biomarkers for liquid biopsy and as novel therapeutic targets. Deciphering the complex circRNA-EMT regulatory network not only deepens our understanding of metastasis but also provides a rational framework for developing precision oncology strategies to intercept metastatic disease.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.